Characteristics of SARS-CoV2 that may be useful for nanoparticle pulmonary drug delivery. (16th March 2022)

• Record Type: Journal Article
• Authors: Rabiei, Morteza; Kashanian, Soheila; Samavati, Seyedeh Sabereh; Derakhshankhah, Hossein; Jamasb, Shahriar; McInnes, Steven J. P.
• Is Part Of: Journal of drug targeting. Volume 30:Number 3(2022)
• Page Start: 233
• Page End: 243
• Publication Date: 2022-03-16
• Subjects: Pulmonary drug delivery -- COVID-19 -- aerosolization -- nanoparticles (NPs) -- lung diseases; Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.1080/1061186X.2021.1971236
• Languages: English
• ISSNs: 1061-186X

Abstract

Abstract: As a non-invasive method of local and systemic drug delivery, the administration of active pharmaceutical ingredients (APIs) via the pulmonary route represents an ideal approach for the therapeutic treatment of pulmonary diseases. The pulmonary route provides a number of advantages, including the rapid absorption which results from a high level of vascularisation over a large surface area and the successful avoidance of first-pass metabolism. Aerosolization of nanoparticles (NPs) is presently under extensive investigation and exhibits a high potential for targeted delivery of therapeutic agents for the treatment of a wide range of diseases. NPs need to possess specific characteristics to facilitate their transport along the pulmonary tract and appropriately overcome the barriers presented by the pulmonary system. The most challenging aspect of delivering NP-based drugs via the pulmonary route is developing colloidal systems with the optimal physicochemical parameters for inhalation. The physiochemical properties of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been investigated as a template for the synthesis of NPs to assist in the formulation of virus-like particles (VLPs) for pharmaceutical delivery, vaccine production and diagnosis assays.